News

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...
Zacks Investment Research on MSN23h
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?
Pfizer's PFE non-COVID operational revenues improved in 2024, driven by its key in-line products like Vyndaqel, Padcev and ...
Hosted on MSN8d
Trump's CDC to launch bombshell Covid vaccine shakeup
Today's long-delayed ACIP meeting harks what we think are early indications of a more relaxed CDC ... It comes amid low ...
MedPage Today on MSN9d
ACIP Endorses RSV Vaccine for At-Risk Adults 50 and Up
The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...
Morningstar25d
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
“With an indication that also includes pregnant ... 2 Schmoele-Thoma B, Zareba AM, Jiang Q, et al. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
PharmExec8d
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...
Mirage News8d
ACIP Expands Pfizer RSV Vaccine for At-Risk Adults 50-59
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices ...
Yahoo Finance25d
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now offers in the EU the broadest RSV vaccine indication ... help prevent RSV in adults aged 18 and older ...